Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer’s Baycol Settlements Coming At Quicker Pace; 785 Suits Settled So Far

Executive Summary

Bayer has seen the pace of Baycol-related settlements quicken following favorable decisions in the first two cases to come to trial, Finance Division Head Klaus Kühn said during Bayer's May 7 quarterly earnings call

You may also be interested in...



Bayer Baycol avoids class action

Minneapolis federal court denies plaintiffs' motion for class action certification. Bayer had argued that possible claims would have comprised too many diverse and individual issues. Baycol settlements accelerated following initial favorable trial court decisions for Bayer (1"The Pink Sheet" May 12, 2003, p. 20). The company has settled more than 1,342 cases in the U.S. to date...

Bayer Baycol avoids class action

Minneapolis federal court denies plaintiffs' motion for class action certification. Bayer had argued that possible claims would have comprised too many diverse and individual issues. Baycol settlements accelerated following initial favorable trial court decisions for Bayer (1"The Pink Sheet" May 12, 2003, p. 20). The company has settled more than 1,342 cases in the U.S. to date...

Barr Cipro Generic Takes 50% Share; Erosion Slow Under Bayer Deal

Barr's generic ciprofloxacin has captured roughly half of Cipro prescriptions after five weeks on the market

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel